Animal health company Elanco (NYSE: ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.2% year on year to $1.37 billion. Guidance for next quarter’s revenue was better than expected at $1.21 billion at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $0.34 per share was 26.5% above analysts’ consensus estimates.
Is now the time to buy Elanco? Find out by accessing our full research report, it’s free.
Elanco (ELAN) Q2 CY2026 Highlights:
- Revenue: $1.37 billion vs analyst estimates of $1.31 billion (10.2% year-on-year growth, 4.2% beat)
- Adjusted EPS: $0.34 vs analyst estimates of $0.27 (26.5% beat)
- Adjusted EBITDA: $288 million vs analyst estimates of $250.2 million (21.1% margin, 15.1% beat)
- The company lifted its revenue guidance for the full year to $5.12 billion at the midpoint from $5.05 billion, a 1.3% increase
- Management raised its full-year Adjusted EPS guidance to $1.13 at the midpoint, a 6.6% increase
- EBITDA guidance for the full year is $1.02 billion at the midpoint, above analyst estimates of $1.00 billion
- Operating Margin: 8.4%, up from 6.8% in the same quarter last year
- Constant Currency Revenue rose 8% year on year, in line with the same quarter last year
- Market Capitalization: $12.79 billion
"Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco.
Company Overview
Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE: ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, Elanco grew its sales at a tepid 2% compounded annual growth rate. This fell short of our benchmarks and is a rough starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Elanco’s annualized revenue growth of 5.7% over the last two years is above its five-year trend, which is encouraging. 
We can dig further into the company’s sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 6.6% year-on-year growth. Because this number aligns with its reported revenue growth, we can see that foreign exchange has not had a meaningful impact on topline. 
This quarter, Elanco reported year-on-year revenue growth of 10.2%, and its $1.37 billion of revenue exceeded Wall Street’s estimates by 4.2%. Company management is currently guiding for a 6.2% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 3.6% over the next 12 months, a slight deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
Adjusted Operating Margin
Elanco has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 18%.
Analyzing the trend in its profitability, Elanco’s adjusted operating margin decreased by 6.2 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 4.3 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.
This quarter, Elanco generated an adjusted operating margin profit margin of 8.4%, down 9.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Elanco’s unimpressive 3.3% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded.
In Q2, Elanco reported adjusted EPS of $0.34, up from $0.26 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Elanco’s full-year EPS to grow 6.2% from $1.06 to $1.13.
Key Takeaways from Elanco’s Q2 Results
It was good to see Elanco beat analysts’ EPS expectations this quarter. We were also excited its EPS guidance for next quarter outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 6.2% to $27.16 immediately following the results.
Elanco had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).
